of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol). (DART)

January 25, 2010 updated by: AstraZeneca
An observational, non-interventional, multi-centre study to provide further information on the utility of test for a predictive marker by investigating the current prevalence of high sensitivity CRP (hs-CRP) testing and characteristics of each CVD risk group.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

4045

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
      • Busan-si, Korea, Republic of
        • Research Site
      • Cheonju-si, Korea, Republic of
        • Research Site
      • Daegu-si, Korea, Republic of
        • Research Site
      • Daejeon-si, Korea, Republic of
        • Research Site
      • Incheon, Korea, Republic of
        • Research Site
      • Incheon-si, Korea, Republic of
        • Research Site
      • Jeonju-si, Korea, Republic of
        • Research Site
      • Kwangju-si, Korea, Republic of
        • Research Site
      • Seoul, Korea, Republic of
        • Research Site
    • Chungchungnam-do
      • Cheonan-si, Chungchungnam-do, Korea, Republic of
        • Research Site
    • Gyeonggi-do
      • Ansan-si, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Anyang-si, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Bucheon-si, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Goyang-si, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Seongnam-si, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Suwon-si, Gyeonggi-do, Korea, Republic of
        • Research Site
      • Uijeongbu-si, Gyeonggi-do, Korea, Republic of
        • Research Site
    • Jeollanam-do
      • Gwangju-si, Jeollanam-do, Korea, Republic of
        • Research Site
      • Suncheon, Jeollanam-do, Korea, Republic of
        • Research Site
    • Jeonllabuk-do
      • Jeonju-si, Jeonllabuk-do, Korea, Republic of
        • Research Site
    • Kangwon-do
      • Chuncheon, Kangwon-do, Korea, Republic of
        • Research Site
      • Chuncheon-si, Kangwon-do, Korea, Republic of
        • Research Site
      • Kang-Neung, Kangwon-do, Korea, Republic of
        • Research Site
      • Wonju-si, Kangwon-do, Korea, Republic of
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.

Description

Inclusion Criteria:

  • Subjects who was diagnosed as diabetes
  • Subjects who was diagnosed as dyslipidaemia or takes lipid lowering medication
  • Clinic visit in the past 6 months more than once

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide their examination and lab result of medical chart.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
2500 patients
Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Investigate LDL-C goal achievement rate according to ADA recommendation
Time Frame: Within the last 6 months from the date of data entry.
Within the last 6 months from the date of data entry.

Secondary Outcome Measures

Outcome Measure
Time Frame
Investigate reduction of 10-year risk for CHD by using UKPDS risk engine
Time Frame: Within the last 6 months from the date of data entry.
Within the last 6 months from the date of data entry.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Study Director: MoonGyu Lee, Ph.D., Samsung Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2009

Study Completion (Actual)

October 1, 2009

Study Registration Dates

First Submitted

June 19, 2009

First Submitted That Met QC Criteria

June 19, 2009

First Posted (Estimate)

June 22, 2009

Study Record Updates

Last Update Posted (Estimate)

January 26, 2010

Last Update Submitted That Met QC Criteria

January 25, 2010

Last Verified

January 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-CKR-DUM-2009/1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Low Density Lipoprotein Cholesterol Goal Achievement

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe